CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. operated as a clinical-stage biopharmaceutical company focused on therapeutics for central nervous system disorders, with a primary objective of developing lasmiditan for the acute treatment of migraine headaches. The company was founded in 2005 by the venture capital firm Pappas Ventures, alongside Dr. James F. White and Art Pappas. Dr. White, who had a distinguished 22-year career at Eli Lilly & Co. in neuroscience and toxicology, provided the deep scientific and industry expertise that shaped CoLucid's initial strategy. Art Pappas, an experienced pharmaceutical executive and venture capital investor, served as the founding CEO and Chairman, leveraging his extensive background from companies like Glaxo Holdings to guide the startup's corporate development. The company's core asset, lasmiditan, was originally discovered at Eli Lilly and was out-licensed to CoLucid in 2005, a time when pain management was not a strategic focus for Lilly.

CoLucid's business model was centered on advancing lasmiditan through the rigorous and costly phases of clinical development to prove its safety and efficacy, with the ultimate goal of securing regulatory approval and commercialization. The company's strategy involved raising capital from a syndicate of venture investors, including Domain Associates, Care Capital, and Novo Ventures, to fund its extensive research and development operations. Lasmiditan represented a new class of drug called a "ditan," designed as a selective serotonin 5-HT1F receptor agonist. This mechanism of action was its key differentiator; unlike the prevalent triptan class of migraine drugs that constrict blood vessels, lasmiditan was developed to alleviate migraine pain without causing vasoconstriction. This feature specifically targeted a significant unmet need in the market: migraine sufferers with or at risk for cardiovascular disease, for whom triptans could be unsafe.

The company developed both an oral tablet for acute treatment by patients and an intravenous formulation for use in urgent care settings. After successfully completing multiple clinical studies, including a pivotal Phase 3 trial that met its primary and secondary endpoints, CoLucid demonstrated lasmiditan's potential. This success culminated in a significant milestone in January 2017, when Eli Lilly and Company announced an agreement to acquire CoLucid in an all-cash transaction valued at approximately $960 million. The acquisition, completed in March 2017, marked a full-circle journey for lasmiditan, returning it to the company where it was originally discovered. CoLucid became a wholly-owned subsidiary of Lilly, which continued the drug's development, eventually gaining FDA approval for what is now marketed as REYVOW®.

Keywords: migraine treatment, lasmiditan, 5-HT1F agonist, biopharmaceutical, clinical trials, central nervous system, vasoconstriction, Pappas Ventures, Eli Lilly, acquisition